title: The worst histologic elements predict prognosis in moderately-differentiated prostate cancer patients with androgen-withdrawal endocrine therapy.
abstract: OBJECTIVE
  We evaluated the prognostic value of the worst histologic elements in 155 patients with moderately-differentiated prostate cancer (Gleason sum 5-7) treated with androgen-withdrawal endocrine therapy.
  
  
  METHODS
  In individual cases, the proportion (%) of medullary/solid combined with columns-and-cords/trabecular (MED & C-C), regarded as the worst histologic elements, determined according to WHO-Mostofi's classification of histologic patterns, within the total adenocarcinoma area obtained from needle specimens was estimated.
  
  
  RESULTS
  Patients with proportion of MED & C-C >5% had a significantly poorer prognosis than those with <5% (p < 0.05). A significant difference was also found in the survival curves of patients grouped by stage (p < 0.01). There was no significant difference among the patients with Gleason sum of 5, 6 and 7. Multivariate analysis showed that stage and MED & C-C had independent prognostic value.
  
  
  CONCLUSIONS
  Proportion of MED & C-C may provide useful prognostic information about patients with moderately-differentiated, Gleason sum 5-7, prostate cancer treated with androgen-withdrawal endocrine therapy.
authors.affiliation: Department of Urology, Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Masuda
authors.forename: M
authors.initials: M
authors.lastname: Iki
authors.forename: S
authors.initials: S
authors.lastname: Noguchi
authors.forename: K
authors.initials: K
authors.lastname: Mikata
authors.forename: Y
authors.initials: Y
authors.lastname: Kubota
authors.forename: M
authors.initials: M
authors.lastname: Harada
authors.forename: M
authors.initials: M
authors.lastname: Hosaka
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use*; D001707:Biopsy, Needle; D005069:Evaluation Studies as Topic; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D011468:Prostatectomy / Q000379:methods; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D018709:Statistics, Nonparametric; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists